Preview Mode Links will not work in preview mode

Jul 9, 2019

Proceedings from a CME symposium held at the 2019 ASCO Annual Meeting. Featuring perspectives from Dr D Ross Camidge, Dr Stephen V Liu, Prof Solange Peters, Dr Gregory J Riely and Dr David R Spigel.

  • Introduction (00:00)
  • Optimal Therapeutic Approaches for Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) and EGFR Tumor Mutations — Dr Riely (3:24)
  • Management of NSCLC with ALK Rearrangements or Other Targetable Abnormalities — Dr Camidge (30:37)
  • Current and Emerging Paradigms in the Treatment of Small Cell Lung Cancer (SCLC) — Dr Liu (56:45)
  • Integration of Immune Checkpoint Inhibition into the Management of Locally Advanced NSCLC — Dr Spigel (1:10:55)
  • Available Data with and Current Clinical Role of Anti-PD-1/PD-L1 Antibodies Alone or in Combination with Other Systemic Therapies for Patients with Metastatic NSCLC — Prof Peters (1:34:06)

Select publications